Physician profile
Mahathi Reddy
NPI 1225131543
$1,095.30
in general payments reported to CMS, 2019-2025
18 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $362 · 2022: $61.92 · 2023: $152 · 2024: $64.04 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $302.84 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $149.59 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $74.61 | 2019-2025 | Farxiga |
| Amgen INC. | $60.41 | 2022-2025 | Krystexxa, Tavneos |
| Medtronic Vascular, INC. | $56.72 | 2020 | |
| Corcept Therapeutics | $53.45 | 2025 | Korlym |
| Aurinia Pharma U.S., INC. | $53.05 | 2023-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $47.39 | 2023 | Tarpeyo |
| Lilly USA, LLC | $46.67 | 2023-2024 | Jardiance |
| Baxter Healthcare | $46.27 | 2022 | |
| Medtronic, INC. | $45.82 | 2023 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.06 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $28.07 | 2019 | |
| Scpharmaceuticals INC. | $22.85 | 2024 | |
| Opko Pharmaceuticals, LLC | $21.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.22 | 2019 | |
| Fresenius USA Marketing, INC. | $15.02 | 2019 | |
| Nuwellis, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahathi Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.